PT - JOURNAL ARTICLE AU - Li, Shuhao AU - Lou, Jingwen AU - Mulatihan, Yelina AU - Xiong, Yuhang AU - Li, Yao AU - Xu, Qi TI - Allium Vegetables Intake and Digestive System Cancer Risk: A Study Based on Mendelian Randomization, Network Pharmacology and Molecular Docking AID - 10.1101/2024.09.18.24313801 DP - 2024 Jan 01 TA - medRxiv PG - 2024.09.18.24313801 4099 - http://medrxiv.org/content/early/2024/09/22/2024.09.18.24313801.short 4100 - http://medrxiv.org/content/early/2024/09/22/2024.09.18.24313801.full AB - Background Allium vegetables (garlic and onion) are one of the flavorings in people’s daily diets. Observational studies suggest that intake of allium vegetables may be correlated with a lower incidence of digestive system cancers. However, the existence of a causal relationship is still controversial due to confounding factors and reverse causation. Therefore, we explored the causal relationship between intake of allium vegetables and digestive system cancers using Mendelian randomization approach.Methods First, we performed Mendelian randomization analyses using inverse variance weighting (IVW), weighted median, and MR-Egger approaches, and demonstrated the reliability of the results in the sensitivity step. Second, Multivariable Mendelian randomization was applied to adjust for smoking and alcohol consumption. Third, we explored the molecular mechanisms behind the positive results through network pharmacology and molecular docking methods.Results The study suggests that increased intake of garlic reduced gastric cancer risk. However, onion intake was not statistically associated with digestive system cancer.Conclusion Garlic may have a protective effect against gastric cancer.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by College Students' Innovative Entrepreneurial Training Plan Pro-gram, item number S202410760052.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study is based on publicly available datasets. These datasets can be found here：https://gwas.mrcieu.ac.uk/ (accessed February 19, 2024) and https://www.ebi.ac.uk/gwas/home (accessed February 20, 2024)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThis study is based on publicly available datasets. These datasets can be found here https://gwas.mrcieu.ac.uk/ (accessed February 19, 2024) and https://www.ebi.ac.uk/gwas/home (accessed February 20, 2024)